FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Woodcock Touts Medical Device Actions

[ Price : $8.95]

FDA acting commissioner Janet Woodcock discusses new agency plans to better secure the medical device supply chain.

Dahlia Center Offering Cellular Product to Treat Covid-19: FDA

[ Price : $8.95]

The CBER Office of Compliance and Biologics Quality cautions The Dahlia Center that it is marketing unapproved cellular products.

Jordans Crossing Selling Unapproved, Misbranded Covid Products: FDA

[ Price : $8.95]

FDA says Jordans Crossing Herbal Connection is marketing a misbranded unapproved new drug intended to prevent or treat Covid-19.

Bladder Cancer Test Gets Breakthrough Status

[ Price : $8.95]

FDA grants AnchorDx a breakthrough device designation for UriFind, an early detection test for bladder cancer based on urine DNA m...

Draft Remanufacturing Guidance Falls Short: Mintz Analysis

[ Price : $8.95]

Mintz attorneys say an FDA draft medical device remanufacturing guidance fails to give information that entities need to determine...

Genentech Breakthrough for Myelodysplastic Drug

[ Price : $8.95]

FDA grants Genentech a breakthrough therapy designation for Venclexta (venetoclax) in combination with azacitidine for treating ad...

Zoll Brain Injury Dashboard Cleared

[ Price : $8.95]

FDA clears a Zoll Medical 510(k) for its TBI Dashboard feature on its Propaq M monitor and Propaq MD monitor/defibrillator for man...

Covis Seeks FDA Actions on Eugia Pharma ANDA

[ Price : $8.95]

Covis asks FDA to determine that Eugia should have filed a 505(b)(2) NDA rather than an ANDA for its proposed generic form of Covi...

A Better Life Marketing Unapproved Stem Cell Therapy: FDA

[ Price : $8.95]

The CBER Office of Compliance and Biologics Quality says A Better Life Stem Cell Center is marketing unapproved cellular products ...

FDA Approvals of High-Risk Medical Devices Way Down: Post

[ Price : $8.95]

An Evaluate Vantage post says FDA approval of high-risk medical devices has dropped in the first half of 2021 due to workload stra...